Werewolf Therapeutics, Inc. (HOWL)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
HOWL Chart
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Werewolf Therapeutics (HOWL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Werewolf Therapeutics, Inc. (HOWL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Werewolf Therapeutics, Inc. ever had a stock split?
Werewolf Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Daniel J. Hicklin CEO | NASDAQ (NGS) Exchange | 95075A107 CUSIP |
| US Country | 46 Employees | - Last Dividend | - Last Split | 30 Apr 2021 IPO Date |
Overview
Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics designed to stimulate the body’s immune system to combat cancer. Leveraging its proprietary PREDATOR platform, the company is committed to designing conditionally activated molecules that activate both adaptive and innate immunity. These developments aim to overcome the limitations associated with conventional proinflammatory immune therapies. Established in 2017 and based in Watertown, Massachusetts, Werewolf Therapeutics is at the forefront of immune-oncology research, striving to make a significant impact in the treatment of cancer.
Products and Services
- WTX-124: This lead product candidate is a conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, currently undergoing a Phase I/Ib clinical trial. It is designed for the treatment of advanced or metastatic solid tumors, utilizing the body's immune response to attack cancer cells more effectively.
- WTX-330: Another key candidate in the pipeline is WTX-330, a conditionally activated Interleukin-12 (IL-12) INDUKINE molecule. It's in Phase I clinical trials targeting the treatment of advanced or metastatic solid tumors and lymphoma, aiming to harness the power of the immune system in a controlled manner to fight malignancies.
- JZP898: This molecule is a conditionally activated interferon alpha (IFN-α) INDUKINE molecule being developed for the comprehensive treatment of cancer. It represents Werewolf Therapeutics’ venture into harnessing interferon's potential to stimulate the immune system against cancer cells.
- WTX-712: Focused on the activated Interleukin-21 (IL-21) INDUKINE molecule, WTX-712 is another innovative product in development aimed at treating cancer. This candidate highlights the company's commitment to exploring various immune pathways for oncology treatment.
- WTX-518: This product entails an activated Interleukin-18 (IL-18) INDUKINE molecule, further expanding the company's portfolio in developing cancer therapies. WTX-518 exemplifies Werewolf Therapeutics' strategic approach to targeting different aspects of the immune system to combat cancer more effectively.
